Given the current data in glioblastoma suggesting a tumor cell-extrinsic function for MIF, it is likely that targeting MIF may be more successful by impacting the TME (immune suppression, angiogenesis) rather than the tumor cells themselves, and this should be explored alone and in combination with known immune modulators and antiangiogenic agents. Here, MIF is linked to neoplasm.